Share on LinkedInShare on LinkedIn

ARTICLE · 16 APRIL 2015

Successful Rule 9(b) Defense Of False Claims Act Whistleblower Litigation

Butler Snow LLP
Butler Snow LLP
Contributor
Butler Snow LLP

Butler Snow LLP

Some law firms promise client service. Butler Snow delivers on that promise. Surveys by respected...

View firm profile
Explore more from Butler Snow LLP

The lure of significant monetary awards continues to stimulate high-risk whistleblower actions under the False Claims Act, and these claims are increasingly common in the pharmaceutical and medical device industry.

United StatesCriminal Law

The lure of significant monetary awards continues to stimulate high-risk whistleblower actions under the False Claims Act (FCA), and these claims are increasingly common in the pharmaceutical and medical device industry. The decision in United States v. Novartis AG, 2015 U.S. Dist. LEXIS 32771 (D. Mass. March 17, 2015), is a bright spot for corporate defendants across all industries, as it underscores the importance of applying Rule 9(b) of the Federal Rules of Civil Procedure in fraud claims under the FCA.

Novartis involved claims by three separate whistleblowers (relators) who worked as sales representatives for Novartis. The whistleblowers alleged that Novartis engaged in fraudulent conduct by: (1) inducing physicians to prescribe the medication Xolair® for off-label, or unapproved, uses; (2) paying illegal kickbacks to prescribing physicians for the promotion of Xolair®; and (3) illegally instructing physicians to use improper medical codes (or "upcoding"),

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from